HomeBUSINESS
BUSINESS

Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
(Feb.13.2018)

LTL Pharma CEO Jiro Mizukawa
LTL Pharma is confident about its business specializing in off-patent brand-name medicines despite the major pricing overhaul this April, which would cut sharply into the prices of these drugs called long-listed products (LLPs), President and CEO Jiro Mizukawa says ...
(LOG IN FOR FULL STORY)